Obesity Drug Candidates From Arena Pharmaceuticals and Vivus Look to Make Big Splash in 2012

Obesity Drug Candidates From Arena Pharmaceuticals and Vivus Look to Make Big Splash in 2012

Five Star Equities Provides Stock Research on Arena Pharmaceuticals & Vivus

NEW YORK, NY--(Marketwire -01/12/12)- Biotechnology firms focused on Obesity drugs have begun to rally in the early stages of 2012 as key FDA meetings are expected to take place this year. The FDA has proven to be quite hesitant towards approving obesity medication in the past due to efficiency concerns and potential side effects. If an obesity drug could make its way to the market, analysts argue the product would have astronomical earnings potential due to the overwhelming number of overweight Americans. Five Star Equities examines the outlook for companies in the Biotechnology industry and provides equity research on Arena Pharmaceuticals, Inc. (NASDAQ: ARNA - News) and Vivus, Inc. (NASDAQ: VVUS - News). Access to the full company reports can be found at:

www.fivestarequities.com/ARNA

www.fivestarequities.com/VVUS

According to eHealthMedicine, each year, Americans spend billions of dollars on dieting, diet foods, diet books, diet pills and another $45 billion is spent on treating the diseases associated with obesity. Moreover, eHealthMedicine argues that businesses suffer an estimated $20 billion loss in productivity each year from absence due to illness caused by obesity.

Presently Vivus is working on Qnexa, an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. Shares of the company surged earlier this week on news that the US FDA requested the removal of the contraindication for pregnant women from the Qnexa obesity drug label.

Five Star Equities releases regular market updates on the biotechnology industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.fivestarequities.com and get exclusive access to our numerous stock reports and industry newsletters.

Arena Pharmaceutical's clinical development programs include lorcaserin that has completed two pivotal Phase III clinical trials for the treatment of weight management, including weight loss and maintenance of weight loss. Shares of ARNA jumped earlier this week after the company announced that that the Food and Drug Administration will make a new ruling on its obesity drug lorcaserin by June 27.

The FDA refused to approve lorcaserin in October 2010 because there was limited effectiveness that it works, and because the drug was linked to tumors in rats during preclinical studies, The Associated Press reports.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.fivestarequities.com/disclaimer
Contact:

Five Star Equities
Email Contact

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.